首页> Annals of oncology : official journal of the European Society for Medical Oncology> Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients.

Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients.

导出原文传递

翻译打印收藏纠错

第一作者： A,Algazi

第一单位： Department of Medicine, University of California, San Francisco, San Francisco, USA.

作者： A,Algazi ^[1] ; S,Bhatia ^[2] ; S,Agarwala ^[3] ; M,Molina ^[4] ; K,Lewis ^[5] ; M,Faries ^[6] ; L,Fong ^[1] ; L P,Levine ^[1] ; M,Franco ^[1] ; A,Oglesby ^[1] ; C,Ballesteros-Merino ^[7] ; C B,Bifulco ^[7] ; B A,Fox ^[7] ; D,Bannavong ^[8] ; R,Talia ^[8] ; E,Browning ^[8] ; M H,Le ^[8] ; R H,Pierce ^[8] ; S,Gargosky ^[8] ; K K,Tsai ^[1] ; C,Twitty ^[8] ; A I,Daud ^[9]

作者单位： Department of Medicine, University of California, San Francisco, San Francisco, USA. ^[1] Department of Medicine, University of Washington, Seattle, USA. ^[2] St. Luke's Cancer Center, Bethlehem, USA. ^[3] Lakeland Health Medical Center, Lakeland, USA. ^[4] University of Colorado Cancer Center - Anschutz, Denver, USA. ^[5] Providence John Wayne Cancer Institute, Santa Monica, USA. ^[6] Earle A. Chiles Research Institute at Providence Portland Medical Center, Portland, USA. ^[7] OncoSec Medical Incorporated, San Diego, USA. ^[8] Department of Medicine, University of California, San Francisco, San Francisco, USA. Electronic address: Adil.daud@ucsf.edu. ^[9]

关键词 IL-12 Immunotherapy Tavokinogene telseplasmid cytokine electroporation intratumoral melanoma